China (Mainland)
High Quality PRASUGREL HYDROCHLORIDE CAS NO.389574-19-0
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
1(1-2)Gram
- Product Details
Keywords
- 389574-19-0
- PRASUGREL HYDROCHLORIDE
- PRASUGREL HYDROCHLORIDE Price
Quick Details
- ProName: High Quality PRASUGREL HYDROCHLORIDE
- CasNo: 389574-19-0
- Molecular Formula: C20H20FNO3S.ClH
- Appearance: White powder
- Application: pharmaceutical intermediates
- DeliveryTime: Qingdao Port
- PackAge: 1kg or 25Kg drum
- Port: QIngdao Port
- ProductionCapacity: 3000 Metric Ton/Year
- Purity: 98% HPLC
- Storage: Store in dry, dark and ventilated plac...
- Transportation: By air or by sea. Prompt delivery
- LimitNum: 1 Gram
- Moisture Content: See data sheet
- Samples: Available
Superiority
We promise our customer following items
1.Reasonable price:
2.Low moq:No worry about the low moq, our moq is 1 gram or lower.
3.Good and efficient service,Fast Delivery
4.Super-good quality
Details
Description
Molecular Formula: C20H21ClFNO3S
Molecular Weight: 409.902
CAS Registry Number: 389574-19-0
InChI: 1/C20H20FNO3S.ClH/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21;/h2-5,10,13,19H,6-9,11H2,1H3;1H
Boiling point: 493.5°C at 760 mmHg
Flash point: 252.3°C
Appearance:white or off-white crystalline powder
Specification: 99%min
Standard: EP/BP/USP
Odor: odorless
Introduction
Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).
Function
For Heart failure, stroke, unstable angina and other cardiovascular and cerebrovascular diseases. Patients with acute coronary syndrome requiring percutaneous coronary intervention.
Specification
|
Item of analysis |
Standard |
Result of analysis |
|
Description |
White Crystalline Powder |
Conforms |
|
Identification |
(1) IR (2) UV |
Conforms |
|
Loss on drying |
≤1.0% |
0.35% |
|
Ordinary impurities |
Single impurity≤0.5% Total impurities≤1.0% |
0.16% 0.49% |
|
Heavy metals |
≤20ppm |
Conforms |
|
Residual solvent |
≤0.2% |
0.09% |
|
Assay |
99.0%~101.0% |
99.5% |
